Literature DB >> 7523224

Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns.

B R Yacyshyn1, A Lazarovits, V Tsai, K Matejko.   

Abstract

BACKGROUND/AIMS: The integrin family of adhesion molecules on intestinal lamina propria mononuclear cells (LPMNC) was studied using fluorescence-activated cell cytometry. These molecules are implicated in extravascular cell migration and are important regulators of disease.
METHODS: Using fluorescence-activated cell cytometry, B- and T-cell subsets in the intestines of 10 normal patients, 11 patients with Crohn's disease, and 8 patients with ulcerative colitis were stained with monoclonal antibodies to a panel of integrins.
RESULTS: Expression of alpha integrins on CD3+ T cells and CD19+ B cells was different in normal and inflammatory bowel disease LPMNC. Ulcerative colitis T cells expressed less beta 1 and alpha 4 and significantly more alpha 2 and alpha 6. There was a difference in alpha 4 and beta 1 expression between LPMNC B cells from Crohn's disease and normal intestines. Sixteen percent of CD19+ LPMNC B cells from Crohn's and 19% of ulcerative colitis LPMNC expressed alpha 2. Crohn's and ulcerative colitis CD19+ LPMNC B cells expressed more alpha 5 integrin than normal specimens. CD3+ T cells and CD19+ B cells expressed alpha 6 only in ulcerative colitis. Ulcerative colitis and Crohn's disease CD19+ LPMNC expressed less alpha 4, consistent with their reciprocal increases of alpha 5 and alpha 2. A difference in beta 7 (Peyer's patch specific) antigen was observed between inflammatory bowel disease and normal LPMNC for both CD3+ and CD19+ LPMNC.
CONCLUSIONS: These findings identify the differences of lymphocyte homing capability in inflammatory bowel disease and normal intestine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523224     DOI: 10.1016/0016-5085(94)90538-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

1.  Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability.

Authors:  B Yacyshyn; J Meddings; D Sadowski; M B Bowen-Yacyshyn
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.

Authors:  B R Yacyshyn; A Schievella; K L Sewell; J A Tami
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

3.  Plasmablast frequency and trafficking receptor expression are altered in pediatric ulcerative colitis.

Authors:  Nicole J Tarlton; Caroline M Green; Nicole H Lazarus; Lusijah Rott; Anthony P Wong; Oren N Abramson; Martina Bremer; Eugene C Butcher; Tzvia Abramson
Journal:  Inflamm Bowel Dis       Date:  2012-04-05       Impact factor: 5.325

4.  Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation.

Authors:  J Meenan; J Spaans; T A Grool; S T Pals; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

5.  Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease.

Authors:  Silvana Geleff; Sebastian F Schoppmann; Georg Oberhuber
Journal:  Virchows Arch       Date:  2003-01-16       Impact factor: 4.064

6.  beta7 Integrin expression is not required for the localization of T cells to the intestine and colitis pathogenesis.

Authors:  B C Sydora; N Wagner; J Lohler; G Yakoub; M Kronenberg; W Muller; R Aranda
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Authors:  B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 8.  Immunotherapy of Crohn's disease.

Authors:  C van Montfrans; L Camoglio; S J van Deventer
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

9.  Leukocyte migration in experimental inflammatory bowel disease.

Authors:  E P Van Rees; M J Palmen; F R Van De Goot; B A Macher; L A Dieleman
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.